New tools for cancer chemotherapy: Computational assistance for tailoring treatments

Molecular Cancer Therapeutics

Volumn 2, Issue 10, 2003, Pages 1079-1084

  Gardner, Shea N ^a   Fernandes, Michael ^b  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^b Medbase LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPUTER PROGRAM; DNA MICROARRAY; DRUG RESISTANCE; HUMAN; KINETICS; METASTASIS; NEOPLASM;

DRUG RESISTANCE, NEOPLASM; HUMANS; KINETICS; NEOPLASM METASTASIS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SOFTWARE;

EID: 2142763766     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (54)

1. Ramaswamy, S. and Golub, T. R. DNA microarrays in clinical oncology. J. Clin. Oncol., 20: 1932-1941, 2001.
2. Ochs, M. F. and Godwin, A. K. Microarrays in cancer: research and applications. Biotechniques, 34: S4-S15, 2003.
3. Shah, M. A. and Schwartz, G. K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res., 7: 2168-2181, 2001.
4. Collecchi, P., Galdini, E., Giannessi, P., Naccarato, A. G., Passoni, A., Gardin, G., Roncella, M., Evangelista, G., Bevilacqua, G., and Conte, P. F. Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. Eur. J. Cancer, 34: 1701-1704, 1998.
5. Diadone, M. G., Costa, A., and Silvestrini, R. Cell proliferation markers in human solid tumors: assessing their impact in clinical oncology. Methods Cell Biol., 64: 359-384, 2001.
6. Silvestrini, R., Daidone, M. G., Luisi, A., Mastore, M., Leutner, M., and Salvadori, B. Cell proliferation in 3,800 node-negative breast cancers: consistency over time of biological and clinical information provided by 3H-thymidine labelling index. Int. J. Cancer (Pred. Oncol.), 74: 122-127, 1997.
7. Höckel, M., Schlenger, K., Höckel, S., and Vaupel, P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res., 59: 4525-4528, 1999.
8. Panetta, J. C. A mathematical model of drug resistance: heterogeneous tumors. Math. Biosci., 147: 41-61, 1997.
9. Xie, X., Clausen, O. P. F., Angelis, P. D., and Boysen, M. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer, 86: 913-920, 1999.
10. Day, R. S. OncoTCap. University of Pittsburgh (PITT), 2000.
11. Gardner, S. N. A mechanistic, predictive model of dose response curves for cell cycle phase-specific and -nonspecific drugs. Cancer Res., 60: 1417-1425, 2000.
12. Gardner, S. N. Modeling multi-drug chemotherapy: tailoring treatment to individuals. J. Theor. Biol., 214: 181-207, 2002.
13. Blagosklonny, M. V. and Pardee, A. B. Unearthing the gems. Nature, 416: 373, 2002.
14. Goldie, J. H. Drug resistance in cancer: a perspective. Cancer Metastasis Rev., 20: 63-68, 2001.
15. Brazma, A., Hingamp, P., Quackenbush, J., Sherlock, G., Spellman, P. Stoeckert, C., Aach, J., Ansorge, W., Ball, C. A., Causton, H. C., Gaasterland, T., Glenisson, P., Holstege, F. C. P., Kim I. F., Markowitz, V., Matese, J. C., Parkinson, H., Robinson, A., Sarkans, U., Schulze-Kremer, S., Stewart, J., Taylor, R., Vilo, J., and Vingron, M. Minimum information about a microarray experiment (MIAME) -toward standards for microarray data. Nat. Genet., 29: 365-371, 2001.
16. Hekstra, D., Taussig, A. R., Magnasco, M., and Naef, F. Absolute mRNA concentrations from sequence-specific calibration of oligonucleotide arrays. Nucleic Acids Res., 31: 1962-1968, 2003.
17. Huang, J., Qi, R., Quackenbush, J., Dauway, E., Lazaridis, E., and Yeatman, T. Effects of ischemia on gene expression. J. Surg. Res., 99: 222-227, 2001.
18. De Jong, H. Modeling and simulation of genetic regulatory systems: a literature review. J. Comput. Biol., 9: 67-103, 2002.
19. Pusztai, L., Ayers, M., Stec, J., and Hortobagyi, G. N. Clinical application of cDNA microarrays in oncology. Oncologist, 8: 252-258, 2003.
20. Kudoh, K., Ramanna, M., Ravatn, R., Elkahloun, A. G., Bittner, M. L., Meltzer, P. S., Trent, J. M., Dalton, W. S., and Chin, K. V. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res., 60: 4161-4166, 2000.
21. Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., Bloomfiled, C. D., and Lander, E. S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 286: 531-537, 1999.
22. Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, K., Smeland, E. B., and Staudt, L. M. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med., 346: 1937-1947, 2002.
23. Lipponen, P. Apoptosis in breast cancer: relationship with other pathological parameters. Endocr.-Relat. Cancer, 6: 13-16, 1999.
24. Murray, J. M. Some optimal control problems in cancer chemotherapy with a toxicity limit. Math. Biosci., 100: 49-67, 1990.
25. Panetta, J. C. A mathematical model of breast and ovarian cancer treated with paclitaxel. Math. Biosci., 146: 89-113, 1997.
26. Swan, G. W. Role of optimal control theory in cancer chemotherapy. Math. Biosci., 101: 237-284, 1990.
27. Clark, P. I., Slevin, M. L., Joel, S. P., Osborne, R. J., Talbot, D. I., Johnson, P. W. M., Reznek, R., Masud, T., Gregory, W., and Wrigley, P. F. M. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J. Clin. Oncol., 12: 1427-1435, 1994.
28. Wolmark, N., Piedbois, P., Rougier, P., Buyse, M., Pignon, J. P., Ryan, L., Hansen, R., Zee, B., Weinerman, B., Pater, J., Leichman, C., Macdonald, J., Benedetti, J., Lokich, J., Harrington, D., McFadden, E., Ribble, A., Jacobeson, R., Luboinski, M., Vaitkevicius, V., LeBourgeois, J. P., Piedbois, Y., Gautheir, E., Durand-Zaleski, I., Carlson, R., Rustum, Y. M., and Erlichman, C. Efficacy of intravenous continuous infusion of flourouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol., 16: 310-308, 1998.
29. Duc, H. N. and Nickolls, P. M. Multicompartment models of cancer chemotherapy incorporating resistant cell populations. J. Pharmacokinet. Biopharm., 15: 145-177, 1987.
30. Souhami, R. L. Will increases in dose intensity improve outcome: con. Am. J. Med., 99 (Suppl. 6A): 71S-76S, 1995.
31. Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J., Hart, R. D., Moore, A., Ellerton, J. A., Norton, L., Ferree, C. R., Ballow, A. C., Frei, E., III, and Henderson, I. C. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N. Engl. J. Med., 330: 1253-1259, 1994.
32. Schimke, R. T. Gene amplification, drug resistance, and cancer. Cancer Res., 44: 1735-1742, 1984.
33. Gardner, S. N. Scheduling chemotherapy: Catch 22 between cell kill and resistance evolution. J. Theor. Med., 2: 1-18, 2000.
34. Hassan, S. B., Johsson, E., Larsson, R., and Karlsson, M. O. Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanismsof action. J. Pharmacol. Exp. Ther., 299: 1140-1147, 2001.
35. Jusko, W. J. A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents. J. Pharmacokinet. Biopharm., 1: 175-200, 1973.
36. Ozawa, S., Sugiyama, Y., Mitsuhashi, M., and Inaba, M. Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. Cancer Res., 49: 3823-3828, 1989.
37. Norton, L. and Simon, R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat. Rep., 61: 1307-1317, 1977.
38. Coldman, A. J. and Murray, J. M. Optimal control for a stochastic model of cancer chemotherapy. Math. Biosci., 168: 187-200, 2000.
39. Norton, L. and Simon, R. The Norton-Simon hypothesis revisited. Cancer Treat. Rep., 70: 163-169, 1986.
40. Agur, Z., Arnon, R., and Schechter, B. Reduction of cytotoxicity to normal tissues by new regiments of cell-cycle phase specific drugs. Math. Biosci., 92: 1-15, 1988.
41. Dibrov, B. F. Resonance effect in self-renewing tissues. J. Theor. Biol., 192: 15-23, 1998.
42. Birkhead, B. G., Rankin, E. M., Gallivan, S., Dones, L., and Rubens, R. D. Amathematical model of the development of drug resistance to cancer chemotherapy. Eur. J. Cancer Clin. Oncol., 23: 1421-1427, 1987.
43. Fister, K. R. and Panetta, J. C. Optimal control applied to cell-cycle specific cancer chemotherapy. SIAM J. Appl. Math., 60: 1059-1072, 2000.
44. Swierniak, A., Polanski, A., and Kimmel, M. Optimal control problems arising in cell-cycle specific cancer chemotherapy. Cell Proliferation, 29: 117-139, 1996.
45. Andersen, L. K. and Mackey, M. C. Resonance in periodic chemotherapy: a case study of acute myelogenous leukemia. J. Theor. Biol., 209: 113-130, 2001.
46. DePas, T., Curigliano, G., Masci, G., Catania, C., Comandone, A., Boni, C., Tucci, A., Pagani, O., Marrocco, E., and de Braud, F. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. Ann. Oncol., 13: 161-166, 2002.
47. Day, R., Shirey, W., Ramakrishnan, S., and Huang, Q. Tumor biology modeling workbench for prospectively evaluating cancer treatments. In: Proceedings of the IEEE /CESA '98: Computational Engineering with Systems Applications, Hammamet, Tunisa, 1998.
48. Day, R. S. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res., 46: 3876-3885, 1986.
49. Goldie, J. H. and Coldman, A. J. Drug Resistance in Cancer, Mechanisms and Models. Cambridge: Cambridge University Press, 1998.
50. Dignam, J. J., Day, R. S., and Bryant, J. Statistical explorations into long-term tamoxifen efficacy in the treatment of early breast cancer. In: Proceedings of the 160th Annual Joint Statistical Meeting (Biometrics Section), 1999.
51. Korn, E. L., Arbuck, S. G., Pluda, J. M., Simon, R., Kaplan, R. S., and Christian, M. C. Clinical trial designs for cytostatic agents: Are new approaches needed? J. Clin. Oncol., 19: 265-272, 2001.
52. Fox, E., Curt, G. A., and Balis, F. M. Clinical trial design for target-based therapy. Oncologist, 7: 401-409, 2002.
53. Schilsky, R. L. End points in cancer clinical trials and the drug approval process. Clin. Cancer Res., 8: 935-938, 2002.
54. Silvestrini, R., Luisi, A., Zambetti, M., Cipriani, S., Valagussa, P., Bonadonna, G., and Daidone, M. G. Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer. Int. J. Cancer, 87: 405-411, 2000.